citiusonc.com (CTOR): Stock Quotes

Current price action for Citius Oncology, Inc. (CTOR) reflects market expectations for a business commercializing immunotherapy to combat T-cell skin lesions, avoiding price dumping due to its orphan drug status. The indicator stands at 0.57. Citius Oncology, Inc. (CTOR) leverages AI and robotics to develop targeted drugs, thereby accelerating the preclinical phase. Prospects for niche leadership are supported by lymphoma treatments currently completing the certification stage.

Market Price: Citius Oncology, Inc. (CTOR) for 08/14/2024 - 11/15/2026

Metric breakdowns and analytics for Citius Oncology, Inc (CTOR)

- stock quotes and analyst forecast:

Stock Price Citius Oncology Inc.|CTOR - Consensus Target

- stock exchange capitalization data:

Market Valuation Citius Oncology Inc.|CTOR - Aggregate Business Value

- issuer book value statistics:

Net Assets per Single Share Citius Oncology|CTOR - Total Stockholders' Equity|Market Value to Book Value Ratio citiusonc.com|CTOR - Aggregate Asset Value

- debt and solvency information:

- company profitability and valuation multiples indicators:

CTOR - Company Net Income|Expected Profit Citius Oncology, Inc.|CTOR - Company Value to Net Income|Projected Price to Earnings Citius Oncology, Inc|CTOR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Citius Oncology|CTOR - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Citius Oncology|CTOR - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months citiusonc.com|CTOR - Earnings per share increase in current year|Earnings growth forecast for next year Citius Oncology, Inc.

- sales and revenue data:

CTOR - Company Total Revenue|Projected Sales Volume Citius Oncology Inc.|CTOR - Market Cap to Revenue|Forward P/S Multiple Citius Oncology, Inc.|CTOR - Annual Revenue Growth (Last Twelve Months)

Comprehensive company analysis:CTOR Citius Oncology, Inc

The price line chart reflects the market capitalization of Citius Oncology, Inc. (CTOR), where the scaling potential of anti-tumor therapy and patent protection directly determine the asset's investment attractiveness. This indicator captures the daily value of the business stake at market close, measuring the consensus valuation of future cash flows from monopoly drug sales following FDA approval, allowing investors to track the dynamics of the company's fundamental value.

Who Citius Oncology, Inc. competes with